Figure 4.

Proportions of randomised and treated patients with ≥3% BSA psoriasis and IGA ≥2 at Week 0 achieving skin responses through Week 52. IGA 0/1 + ≥2-grade decrease from baseline (A), IGA 0 (B), PASI 90 (C), PASI 100 (D) and PASI 75 (E) response rates derived with application of data handling rules (see Methods). Previously reported Week24 data¹⁴ included for reference. Of 78 patients randomised to receive placebo who had ≥3% BSA psoriasis involvement and IGA ≥2 at baseline, 68 crossed over to guselkumab 100 mg Q4W (after Week24 response assessments); the 10 patients who received only placebo before discontinuing study agent were included as non-responders at Week52. BSA, body surface area; GUS, guselkumab; IGA, Investigator’s Global Assessment; PASI, Psoriasis Area and Severity Index; PBO, placebo; Q4/8W, every 4/8 weeks.